Ami Fadia
Stock Analyst at Needham
(4.55)
# 249
Out of 5,241 analysts
336
Total ratings
50.99%
Success rate
30.14%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $186 → $183 | $145.66 | +25.64% | 30 | May 7, 2026 | |
| ALKS Alkermes | Maintains: Buy | $45 → $50 | $37.48 | +33.40% | 5 | May 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $255 → $267 | $227.72 | +17.25% | 21 | May 5, 2026 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $510 | $342.58 | +48.87% | 18 | Apr 14, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $37 | $28.73 | +28.79% | 1 | Apr 8, 2026 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $185 | $158.42 | +16.78% | 18 | Apr 6, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Hold | n/a | $39.60 | - | 2 | Mar 31, 2026 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $8 | $1.84 | +334.78% | 11 | Mar 31, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $24 → $15 | $4.45 | +237.08% | 22 | Mar 18, 2026 | |
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $4.02 | +248.69% | 2 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.16 | +113.18% | 21 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $32 | $21.39 | +49.60% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $44 | $30.09 | +46.23% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $235 | $228.77 | +2.72% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $32.68 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $21.40 | +35.51% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $192.95 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $14.51 | +2,106.14% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.64 | +231.27% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $10.61 | +493.78% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $34.29 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $0.85 | +2,488.24% | 4 | Jan 3, 2018 |
Revolution Medicines
May 7, 2026
Maintains: Buy
Price Target: $186 → $183
Current: $145.66
Upside: +25.64%
Alkermes
May 6, 2026
Maintains: Buy
Price Target: $45 → $50
Current: $37.48
Upside: +33.40%
Axsome Therapeutics
May 5, 2026
Maintains: Buy
Price Target: $255 → $267
Current: $227.72
Upside: +17.25%
Praxis Precision Medicines
Apr 14, 2026
Reiterates: Buy
Price Target: $510
Current: $342.58
Upside: +48.87%
MapLight Therapeutics
Apr 8, 2026
Initiates: Buy
Price Target: $37
Current: $28.73
Upside: +28.79%
Neurocrine Biosciences
Apr 6, 2026
Reiterates: Buy
Price Target: $185
Current: $158.42
Upside: +16.78%
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $39.60
Upside: -
Neumora Therapeutics
Mar 31, 2026
Reiterates: Buy
Price Target: $8
Current: $1.84
Upside: +334.78%
Bicycle Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $24 → $15
Current: $4.45
Upside: +237.08%
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $4.02
Upside: +248.69%
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.16
Upside: +113.18%
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $21.39
Upside: +49.60%
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $30.09
Upside: +46.23%
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $228.77
Upside: +2.72%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $32.68
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $21.40
Upside: +35.51%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $192.95
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $14.51
Upside: +2,106.14%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.64
Upside: +231.27%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $10.61
Upside: +493.78%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $34.29
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $0.85
Upside: +2,488.24%